Psychological Well-Being of Adolescents Utilizing Puberty Blockers
Overview
This study examines the mental health outcomes of transgender youths using puberty blockers compared to those not using them and cisgender youths.
Background
Transgender youths in the US experience significant mental health disparities, including higher rates of mood disorders and suicidality compared to their cisgender peers. The use of puberty blockers as a reversible intervention has been a topic of research, yet their use is increasingly politicized, leading to calls for further research on their effects.
Data Highlights
This study utilized a nationwide sample from the Mount Sinai Institute for Health Equity Research Multi-Payer Claims Database, covering various payer types and including cohorts of transgender and cisgender youths.
Key Findings
The study included four mutually exclusive cohorts: transgender youths using puberty blockers, transgender youths not using them, cisgender youths using puberty blockers, and cisgender youths not using them.
Puberty blockers have been used since the 1960s for cisgender children with precocious puberty and adapted for gender-affirming care in the 1990s.
Major medical organizations support the use of puberty blockers for transgender youths.
There is a lack of studies using claims data to assess the population associations of puberty blockers among transgender and cisgender youths.
Clinical Implications
The findings highlight the potential mental health benefits of puberty blockers for transgender youths, suggesting that their use may mitigate mood disorders and suicidality. Clinicians should consider these outcomes when discussing treatment options with transgender patients and their families.
Conclusion
The study underscores the importance of understanding the mental health impacts of puberty blockers in transgender youths, particularly in the context of ongoing legislative debates surrounding gender-affirming care.
